Science & Research
How GLP-1 receptor agonists work, what the studies actually say, and why "Ozempic muscle loss" is the real story.
- STEP Young Trial: Wegovy Results in Kids Aged 6 to 117 minSTEP Young trial results explained: semaglutide (Wegovy) cut BMI 13.5% in kids aged 6 to 11 in NEJM, Nov 2026. Side effects, growth, and is it approved yet.
- Wegovy Food Noise: Does It Stop It? New 2026 Data5 minWegovy food noise: new ObesityWeek 2026 data from 26,213 shot users and 6,180 pill users show scores fell within a month. What it means, and if it comes back.
- Ozempic Fetal Oxygen Study: What the Sheep Data Show6 minThe Ozempic fetal oxygen study gave semaglutide to 7 pregnant sheep. Fetal oxygen fell about 19% in two hours. See what it means and what the labels say.
- GLP-1 Non Responders: New Gene Study and What It Means6 minGLP-1 non responders lose little weight on the drug. A new Nature Metabolism study ties some cases on semaglutide to rare GLP1R gene variants. See the numbers.
- Ozempic Muscle Loss: What the Studies Show and How to Prevent It6 minOzempic muscle loss explained: how much lean mass people lose on semaglutide, what the new T-REx lifting study found, and 5 steps to protect your muscle.
- GLP-1 Brain Effects: Brain Fog, Dementia Risk, New Science6 minGLP-1 brain effects explained: how these drugs act on the brain, whether they cause brain fog, what the dementia and Alzheimer's trials found, and when to call.
- GLP-1 Cancer Risk: What the Biggest Studies Show (2026)7 minGLP-1 cancer risk explained: large studies link Ozempic-type drugs to fewer obesity-related cancers, with a kidney cancer signal and a thyroid warning to know.
- CT-G32: Celltrion's Quadruple Agonist Obesity Drug Explained5 minCT-G32 (SCO-940) is Celltrion's quadruple agonist that hits GLP-1, GIP, glucagon and amylin. What the animal data show, vs retatrutide, and when trials start.
- Natural Ozempic: The BRP Discovery and Alternatives That Work6 minNatural Ozempic explained: what Stanford's BRP peptide is, why it is not a supplement, and how honest natural Ozempic alternatives compare with the real drug.
- GLP-1 for Prediabetes: New AHA Study vs Metformin (2026)6 minGLP-1 for prediabetes: a Nov 2026 AHA study of 256,492 adults tied GLP-1s to 31% less type 2 diabetes than metformin. What it means, approvals, insurance.
- Gastric Sleeve vs GLP-1: Weight Loss, Diabetes, Risks6 minGastric sleeve vs GLP-1 drugs like Wegovy and Zepbound: weight loss numbers, diabetes remission data, who qualifies, risks, and using a GLP-1 after surgery.
- GLP-1 Medications and Eating Disorders: 2026 Research7 minGLP-1 medications and eating disorders: how many patients use them, the new 2026 expert rules on screening, who should avoid them, and the warning signs.
- GLP-1 and Aging: Do Ozempic-Type Drugs Slow Aging? (2026)6 minGLP-1 and aging: what the 2026 mouse lifespan study, aging-clock data from Novo and Lilly, and FDA labels say about these drugs for older adults and longevity.
- GLP-1 Heart Muscle Loss: Do These Drugs Shrink the Heart?7 minGLP-1 heart muscle loss explained: a mouse study found smaller hearts on semaglutide, and human heart scans show lower LV mass. What it means and when to worry.
- EloraTZP: Lilly's Eloralintide + Tirzepatide Combo Explained6 minEloraTZP is Eli Lilly's eloralintide plus tirzepatide combo. Phase 2b showed up to 23.3% weight loss. Results, side effects and the AMPLIFY-1 phase 3 trial.
- GLP-1 and Crohn's Disease or Ulcerative Colitis: The Evidence7 minGLP-1 and Crohn's disease: can you take Ozempic, Wegovy or Zepbound with Crohn's or ulcerative colitis? What 2026 studies show on flares, safety and diet.
- UBT251: Novo Nordisk's Triple Agonist, Results and Phase 36 minUBT251 is a weekly GLP-1, GIP and glucagon triple agonist licensed by Novo Nordisk. Phase 2 showed up to 19.7% weight loss. Results, side effects, vs retatrutide.
- Apitegromab (Isembyld): The Muscle Drug Tested With Zepbound6 minApitegromab (Isembyld) is Scholar Rock's FDA-approved SMA drug. In the EMBRAZE trial it halved lean mass loss on tirzepatide. Results, safety and status.
- GLP-1 for Addiction: What the Research Shows in 20266 minGLP-1 for addiction: what trials show for alcohol, opioids and smoking, why telehealth now prescribes it off-label, and what it costs. Plain-English guide.
- Trevogrumab: Regeneron's Muscle-Saving Drug for GLP-1 Users6 minTrevogrumab, Regeneron's anti-myostatin antibody, cut lean mass loss on semaglutide in the COURAGE trial. Results, side effects, garetosmab and status.
- The Major GLP-1 Trials, Summarized: STEP, SURMOUNT, SUSTAIN, SURPASS4 minFive major trial programs underpin everything we know about GLP-1 weight loss. Here is a plain-English summary of what each one showed.
- GLP-1 and Cardiovascular Health: The SELECT Trial and Beyond4 minGLP-1 medications reduce major cardiovascular events independently of weight loss. Here is what the SELECT trial showed and what it means for who should be on these drugs.
- GLP-1 and Bone Density: The Risk No One Talks About4 minRapid weight loss can decrease bone density — especially in postmenopausal women. Here is the science, the risk factors, and the resistance training and supplementation protocol.
- 12 Common Myths About GLP-1 Medications, Debunked4 minFrom "it just makes you sick" to "Ozempic causes cancer" — here are the most common GLP-1 myths and what the actual evidence says.
- GLP-1 and Insulin Resistance: How These Drugs Reverse the Core Problem4 minInsulin resistance is the metabolic foundation of type 2 diabetes and most obesity. Here is how GLP-1 medications attack it from multiple angles.
- GLP-1 for Fatty Liver Disease (NAFLD/MASH): Why It Works3 minNon-alcoholic fatty liver disease (now called MASH) responds dramatically to GLP-1 medications. Here is the mechanism, the data, and what to expect.
- Leptin, Ghrelin, and Why Your Body Fights Weight Loss4 minThe hunger and satiety hormones don't cooperate with weight loss. Here is how leptin and ghrelin work, why they fight regain, and how GLP-1 changes the equation.
- Sarcopenia, Aging, and GLP-1: Why Older Adults Need to Be Especially Careful4 minAge-related muscle loss is the long-term risk factor most amplified by GLP-1 weight loss. Here is what sarcopenia is, why it matters, and the protocol that protects.
- How GLP-1 Affects Your Metabolism (and What "Metabolic Adaptation" Means)4 minWeight loss lowers metabolic rate — that's "metabolic adaptation," and GLP-1 weight loss is no exception. Here is the science and what to do about it.
- What the Research Actually Shows About GLP-1 Rebound Weight Gain4 minStudies of patients stopping GLP-1 medications consistently show significant rebound. Here is what the data actually says, why it happens, and what predicts who keeps the weight off.
- GLP-1 vs GIP: The Two Gut Hormones Behind Modern Weight-Loss Drugs3 minGLP-1 and GIP are the two "incretin" hormones your gut releases after meals. Here's how they differ, why activating both at once is more effective, and what that means for next-generation drugs.
- How GLP-1 Receptor Agonists Actually Work in Your Body3 minGLP-1 medications mimic a gut hormone you already make. Here's the biology of why they suppress appetite, slow digestion, and change blood sugar — without the marketing fluff.
Lose fat. Not muscle.
One protein number, one 20-minute workout, one score. Every day.